Stories > GLP-1 Agonists and Weight-Loss Drugs Dominate Q3 Earnings Calls

GLP-1 Agonists and Weight-Loss Drugs Dominate Q3 Earnings Calls

Diabetes Drug Markets' Growth and Domina...

Eli Lilly Acquires Versanis Bio

Eli Lilly to Build $2.5B Plant for Weigh...

Amgen's Weight-Loss Drugs Market Entranc...

Analyst Recommendations Impact Diverse C...

Anti-Obesity Meds' Impact on Allurion Pr...